Kesimpta More Effective, Costs Less Than Most DMTs for RRMS: Analysis
"The results showed Kesimpta is dominant — that is, associated with greater effectiveness (more QALYs) and lower costs — over other medications indicated for first-line treatment of RRMS. These included Aubagio (teriflunomide), interferon-based therapies, Tecfidera (dimethyl fumarate), and Ocrevus (ocrelizumab)."
Kesimpta for RRMS More Cost-effective Than Most DMTs: Analysis | Canadian Analysis Finds Possible Lifetime Savings Up to CA$41K | Multiple Sclerosis News Today
"The results showed Kesimpta is dominant — that is, associated with greater effectiveness (more QALYs) and lower costs — over other medications indicated for first-line treatment of RRMS. These included Aubagio (teriflunomide), interferon-based therapies, Tecfidera (dimethyl fumarate), and Ocrevus (ocrelizumab)."
Kesimpta for RRMS More Cost-effective Than Most DMTs: Analysis | Canadian Analysis Finds Possible Lifetime Savings Up to CA$41K | Multiple Sclerosis News Today